Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements.

ABSTRACT:

Background and objectives

This study aimed to compare the efficacy of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and brigatinib in the treatment of advanced non-small-cell lung cancer (NSCLC) with ALK rearrangements based on real-world data.

Design and methods

We conducted a multicenter retrospective study using the Clinical Data Warehouse from seven university hospitals affiliated with the Catholic Medical Center. Patients diagnosed with ALK-positive advanced NSCLC and treated with alectinib or brigatinib were included. Key outcomes such as time to discontinuation (TTD), duration of response (DOR), overall survival (OS), and objective response rate (ORR) were analyzed.

Results

A total of 143 patients were includ

SUBMITTER: Kim K 

PROVIDER: S-EPMC11806492 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature